{"postfix": "evotec-aktie", "name": "EVOTEC", "wkn": "566480", "time": "2020.06.02 12:43", "ts": 1591094635, "features": {"KGV": "92.28", "Marktkapitalisierung": {"Size": "Mrd", "Value": "3.67"}, "GA": "0.25", "KBV": "7.24", "BA": "3.19", "KCV": "81.82", "CA": "0.28", "Vola30": "23.87", "Vola90": "52.1", "Vola180": "46.76", "Vola250": "44.01"}, "rivals": ["bb_biotech-aktie", "morphosys-aktie", "qiagen-aktie", "amgen-aktie", "roche_2-aktie", "novartis-aktie", "pfizer-aktie"], "text_data": {"de": [["31.05.20", "Mai 2020: So haben Analysten ihre Einstufung der EVOTEC SE-Aktie angepasst"], ["26.05.20", "Evotec setzt auf k\u00fcnstliche Intelligenz - Aktie vor neuem Kaufsignal"], ["15.05.20", "Evotec und Morphosys: Die deutschen Biotechs geben wieder Gas!"], ["15.05.20", "Citi: Evotec - Warten auf den Befreiungsschlag!"], ["15.05.20", "Citi: Evotec - Warten auf den Befreiungsschlag!"], ["14.05.20", "AKTIE IM FOKUS: Evotec versuchen nach Zahlen Ausbruch aus Abw\u00e4rtstrend"], ["14.05.20", "ROUNDUP: Evotec best\u00e4tigt trotz Corona-Krise Prognosen - Aktie im Plus"], ["14.05.20", "Evotec best\u00e4tigt Prognose - nimmt die Aktie jetzt wieder Fahrt auf?"], ["14.05.20", "Evotec bekr\u00e4ftigt nach gutem Jahresauftakt Prognose"], ["13.05.20", "Ausblick: Evotec legt die Bilanz zum abgelaufenen Quartal vor"], ["30.04.20", "Evotec mit starken News: US-Kooperation zur Suche nach Corona-Antik\u00f6rpern"], ["30.04.20", "Evotec US-Tochter kooperiert mit Ology Bio bei Corona-Antik\u00f6rpern"], ["29.04.20", "Erste Sch\u00e4tzungen: Evotec legt Quartalsergebnis vor"], ["27.04.20", "Biotech-Branche hofft auf Durchbruch bei Corona-Forschungen"], ["22.04.20", "Evotec: Alleinige Rechte an \u201epotenziell revolution\u00e4rer Behandlungsoption\u201c"], ["22.04.20", "Evotec entwickelt Diabetes-Ersatztherapie wieder allein - Aktie legt zu"], ["16.04.20", "Evotec: Neuer Deal, neuer Schwung f\u00fcr die Aktie"], ["06.04.20", "Evotec: Der n\u00e4chste Deal - Aktie gibt kr\u00e4ftig Gas"], ["06.04.20", "Biotechunternehmen Evotec baut Zusammenarbeit mit Takeda aus"], ["02.04.20", "Evotec: Neuer Deal - das steckt dahinter"], ["31.03.20", "Evotec: Neue Partnerschaft - neuer Schwung f\u00fcr die Aktie?"], ["28.03.20", "Evotec: Quartalsergebnisse zum j\u00fcngsten Jahresviertel"], ["28.03.20", "EVOTEC SE: Bilanz zum abgelaufenen Quartal"]], "en": [["29.05.20", "Evotec SE : Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["26.05.20", "Evotec SE : EVOTEC PARTICIPATES IN EXSCIENTIA'S FINANCING ROUND"], ["14.05.20", "Evotec SE : EVOTEC SE REPORTS FIRST QUARTER 2020 RESULTS AND PROVIDES CORPORATE UPDATE"], ["07.05.20", "Evotec SE : EVOTEC SE TO REPORT FIRST QUARTER 2020 RESULTS ON 14 MAY 2020"], ["04.05.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["30.04.20", "Evotec SE : Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["30.04.20", "Evotec SE : JUST - EVOTEC BIOLOGICS TO COLLABORATE WITH OLOGY BIOSERVICES ON ANTIBODIES AGAINST CORONAVIRUS"], ["23.04.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["22.04.20", "Evotec SE : EVOTEC REGAINS GLOBAL RIGHTS TO BETA CELL REPLACEMENT THERAPY"], ["14.04.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["06.04.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["31.03.20", "Evotec SE : Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["26.03.20", "Evotec SE fiscal year 2019 results: Excellent 2019 performance; very good outlook for continued growth 2020"], ["25.03.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["25.03.20", "Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic"], ["19.03.20", "Evotec SE to report fiscal year 2019 results on 26 March 2020"], ["16.03.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["16.03.20", "Evotec Statement on COVID-19"], ["06.03.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["28.02.20", "Evotec SE : Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["27.02.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["27.02.20", "First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis"], ["14.02.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["07.02.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["05.02.20", "Infographic: How to find effective endometriosis treatments"], ["31.01.20", "Evotec SE : Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["30.01.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["30.01.20", "Evotec and Bayer advance further programme into Phase I clinical development"], ["23.01.20", "Evotec and Indivumed announce second joint drug discovery programme"], ["21.01.20", "Evotec SE : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution"], ["20.01.20", "Evotec SE : Increase of profitability guidance for financial year 2019"], ["20.01.20", "Evotec SE: Increase of profitability guidance for financial year 2019"], ["16.01.20", "Just - Evotec Biologics announces product development and manufacturing agreement with OncoResponse"], ["14.01.20", "Just - Evotec Biologics initiates construction of first J.POD\u00ae facility in North America"], ["09.01.20", "Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome"], ["07.01.20", "Evotec and Bristol-Myers Squibb expand iPSC collaboration"], ["02.01.20", "Evotec to attend upcoming investor conferences"], ["2020-05-28 06:45", "BRIEF-N4 Pharma Says Evotec To Move To Second Phase Of Work On COVID-19 Project ...  Financial Government Solutions Legal Reuters News Agency Risk Management Solutions Tax & Accounting Blog: Answers On Innovation @ Thomson Reuters Directory of sites Login Contact Support Business Markets World Politics TV More United States Healthcare May 28, 2020 / 6:49 AM / in 20 minutes BRIEF-N4 Pharma Says Evotec To Move To Second Phase Of Work On COVID-19 Project 1 Min Read May 28 (Reuters) - N4 Pharma PLC: * N4 PHARMA PLC- COVID-19 PROJECT UPDATE * N4 PHARMA PLC- EVOTEC WILL NOW MOVE TO SECOND PHASE OF WORK Source text for Eikon: Further company coverage: Our Standards: The Thomson Reuters Trust Principles. 0 : 0 narrow-browser-and-phone medium-browser-and-portrait-tablet landscape-tablet medium-wide-browser wide-browser-and-larger medium-browser-and ... "], ["2020-05-28 06:45", "BRIEF-N4 Pharma Says Evotec To Move To Second Phase Of Work On COVID-19 Project ...  Government Solutions Legal Reuters News Agency Risk Management Solutions Tax & Accounting Blog: Answers On Innovation @ Thomson Reuters Directory of sites Login Contact Support Business Markets World UK TV More United Kingdom Healthcare May 28, 2020 / 6:47 AM / Updated 12 minutes ago BRIEF-N4 Pharma Says Evotec To Move To Second Phase Of Work On COVID-19 Project 1 Min Read May 28 (Reuters) - N4 Pharma PLC: * N4 PHARMA PLC- COVID-19 PROJECT UPDATE * N4 PHARMA PLC- EVOTEC WILL NOW MOVE TO SECOND PHASE OF WORK Source text for Eikon: Further company coverage: Our Standards: The Thomson Reuters Trust Principles. 0 : 0 narrow-browser-and-phone medium-browser-and-portrait-tablet landscape-tablet medium-wide-browser wide-browser-and-larger medium-browser-and ... "], ["2020-05-26 16:34", "Dundee drug discovery firm Exscientia raises $60 million ... raises $60 million by Rob McLaren May 26 2020, 5.34pm Updated: May 26 2020, 5.36pm Chief executive and founder of Exscientia Professor Andrew Hopkins. Dundee-based drugs discovery company Exscientia has raised $60 million in its latest financing round. The staggering sum realised by the Dundee University spin-out was led by new investor Novo Holdings, with existing investors Evotec, Bristol Myers Squibb, and GT Healthcare Capital also participating in the Series C round. Exscientia, which operates from River Court at City Quay, and Oxford, said the new capital will be used to expand its product pipeline and to launch new products. Established in 2012 by Professor Andrew Hopkins, the life sciences firm uses artificial intelligence (AI) and machine learning to ... "], ["2020-05-14 21:45", "Antibiotics Deals Directory 2010-2020: Trends, Financials And Players - Antibiotics, Aminoglycosides, Cephalosporin, Clindamycin, Macrolides, Penicillin, Quinolones, Sulfonamides, Tetracycline ...  Debiopharm Decibel Therapeutics Defence Science and Technology Laboratory Defense Threat Reduction Agency Deinove Department of Defense Department of Health and Human Services Dipexium Pharmaceuticals Discuva DSM Sinochem Pharmaceuticals Durata Therapeutics Eddingpharm Eli Lilly Emergent BioSolutions Entasis Therapeutics Enterome Bioscience Euprotec Eurofarma Everest Medicines Evolva Evotec Federal Ministry of Education and Research (BMBF) Fedora Pharmaceuticals Ferrer International Flemish agency for Innovation by Science and Technology Foamix FOB Synthesis Forge Therapeutics Foundation for Innovative New Diagnostics FSC Laboratories Galapagos Genentech Geom Therapeutics Gilead Sciences GlaxoSmithKline Global Antibiotic Research and Development Partnership ... "], ["2020-05-14 05:52", "FIRMEN-BLICK-Ergebnis von Evotec stagniert - Ziele bekrftigt ...  News Agency Risk Management Solutions Tax & Accounting Blog: Answers On Innovation @ Thomson Reuters Directory of sites Login Contact Support Business Markets World Politics TV More United States Biotechnology May 14, 2020 / 5:57 AM / Updated 19 minutes ago FIRMEN-BLICK-Ergebnis von Evotec stagniert - Ziele bekrftigt 9 Min Read 14. Mai (Reuters) - Es folgt der Reuters-Blick zu wichtigen Entwicklungen aus der Unternehmenswelt ber die Top-Themen des Tages hinaus: EVOTEC - Frankfurt: Das Biotechunternehmen ist im ersten Quartal beim Ergebnis nicht vom Fleck gekommen. Der bereinigte operative Gewinn stagnierte bei 30 Millionen Euro, wie das Hamburger Unternehmen am Donnerstag mitteilte. Der Umsatz stieg indes um 15 Prozent auf 119,4 Millionen Euro, obwohl ... "], ["2020-05-14 04:20", "German stocks - Factors to watch on May 14 ...  of \"deep\" job cuts as it braces for a prolonged coronavirus crisis after furloughing thousands of workers, industry sources said, though no decision is imminent. TEAMVIEWER Private equity investor Permira placed 25 million shares in the software company at 41 euros per share with institutional investors, it said. This represents about 12.5% of Teamviewer's entire share capital. EVOTEC Q1 results due DUERR Q1 results due SCOUT24 Q1 results due TAG IMMOBILIEN Q1 results due PATRIZIA The real estate group lowered the bottom end of its 2020 profit target range. BILFINGER Q1 results due CECONOMY Fiscal Q2 results due DEUTSCHE EUROSHOP Q1 results due INDUS Q1 results due JOST WERKE Q1 results due SMA SOLAR Q1 results due SUEDZUCKER Fiscal 2019 ... "], ["2020-05-14 04:20", "German stocks - Factors to watch on May 14 ...  of \"deep\" job cuts as it braces for a prolonged coronavirus crisis after furloughing thousands of workers, industry sources said, though no decision is imminent. TEAMVIEWER Private equity investor Permira placed 25 million shares in the software company at 41 euros per share with institutional investors, it said. This represents about 12.5% of Teamviewer's entire share capital. EVOTEC Q1 results due DUERR Q1 results due SCOUT24 Q1 results due TAG IMMOBILIEN Q1 results due PATRIZIA The real estate group lowered the bottom end of its 2020 profit target range. BILFINGER Q1 results due CECONOMY Fiscal Q2 results due DEUTSCHE EUROSHOP Q1 results due INDUS Q1 results due JOST WERKE Q1 results due SMA SOLAR Q1 results due SUEDZUCKER Fiscal 2019 ... "], ["2020-05-13 23:15", "Cystic Fibrosis Pipeline Landscape 2020: Therapeutics Development & Assessment, Companies Involved, Drug Profiles ...  AG CrowdOut Therapeutics CSA Biotechnologies LLC Cyclacel Pharmaceuticals Inc Cyclenium Pharma Inc Daiichi Sankyo Co Ltd Destiny Pharma Plc DiscoveryBiomed Inc Druggability Technologies Holdings Ltd Editas Medicine Inc Eloxx Pharmaceuticals Inc EmphyCorp Inc EnBiotix Inc Enterprise Therapeutics Ltd Entrinsic Health Solutions, Inc. Enzyvant Sciences Ltd Errant Gene Therapeutics LLC Evaxion Biotech ApS Evotec SE Exotect LLC Galapagos NV Galenus Therapeutics Inc Generation Bio Corp Genzyme Corp Grupo Praxis Pharmaceutical SA Helperby Therapeutics Group Ltd Horizon Therapeutics PLC Icagen Inc Idorsia Pharmaceutical Ltd Immun System IMS AB Insmed Inc Invion Ltd Ionis Pharmaceuticals Inc Kamada Ltd Kither Biotech Srl Kyorin Pharmaceutical Co Ltd Lakewood-Amedex ... "], ["2020-05-06 11:15", "Non-Animal Alternatives Testing Market Outlook, 2030: Cellular Assay, Biochemical Assay, In Silico, Ex-vivo ... , Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Companies Mentioned Abbott Laboratories Agilent Technologies, Inc. Bare Blossom Billy Jealousy Bio-Rad Laboratories BioIVT BiomimX SRL BioReliance Corporation (a subsidiary of Merck KGaA) Catalent, Inc Charles River Laboratories, Inc. Cyprotex Ecco Bella Ecotec AG (Cyprotex plc) Elveflow Emulate Inc. Evotec AG (Cyprotex plc) GE Healthcare Gentronix Limited HRel Corporation Laboratory Corporation of America Holdings MB Research Laboratories Modern Minerals Makeup MuLondon Organic Promega Corporation Qiagen N.V. SGS SA SIMULAB Thermo Fisher Scientific Urban Decay VITROCELL For more information about this report visit https://www.researchandmarkets.com/r/i5915w Research and ... "], ["2020-05-04 16:00", "Global Compound Management Industry ...  factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific . All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies. - Competitors identified in this market include, among others, Biosero Inc. Brooks Automation, Inc. Evotec AG Frontier Scientific, Inc. Hamilton Company Icagen Corporation Labcyte, Inc. TCG Lifesciences Pvt., Ltd. Tecan Group Ltd. Ttp Group WuXi AppTec Read the full report: https://www.reportlinker.com/p05798218/?utm_source=PRN I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Compound Management: A PreludeEvolution of Drug Discovery: An ... "]]}}